These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29618310)

  • 21. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.
    Jurecka A; Krumina Z; Żuber Z; Różdżyńska-Świątkowska A; Kłoska A; Czartoryska B; Tylki-Szymańska A
    Am J Med Genet A; 2012 Feb; 158A(2):450-4. PubMed ID: 22246721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic analysis of 17 children with Hunter syndrome: identification and functional characterization of four novel mutations in the iduronate-2-sulfatase gene.
    Chistiakov DA; Kuzenkova LM; Savost'anov KV; Gevorkyan AK; Pushkov AA; Nikitin AG; Vashakmadze ND; Zhurkova NV; Podkletnova TV; Namazova-Baranova LS; Baranov AA
    J Genet Genomics; 2014 Apr; 41(4):197-203. PubMed ID: 24780617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 38.8 kb deletion mutation of the iduronate-2-sulfatase gene in a patient with Hunter syndrome.
    Chou YY; Chao SC; Kuo PL; Lin SJ
    J Formos Med Assoc; 2005 Apr; 104(4):273-5. PubMed ID: 15909065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction.
    Podetz-Pedersen KM; Laoharawee K; Singh S; Nguyen TT; Smith MC; Temme A; Kozarsky K; McIvor RS; Belur LR
    Hum Gene Ther; 2023 Jan; 34(1-2):8-18. PubMed ID: 36541357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermediate form of mucopolysaccharidosis type II (Hunter disease): a C1327 to T substitution in the iduronate sulfatase gene.
    Sukegawa K; Tomatsu S; Tamai K; Ikeda M; Sasaki T; Masue M; Fukuda S; Yamada Y; Orii T
    Biochem Biophys Res Commun; 1992 Mar; 183(2):809-13. PubMed ID: 1550586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis.
    Sukegawa-Hayasaka K; Kato Z; Nakamura H; Tomatsu S; Fukao T; Kuwata K; Orii T; Kondo N
    J Inherit Metab Dis; 2006 Dec; 29(6):755-61. PubMed ID: 17091340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
    Catalano F; Vlaar EC; Dammou Z; Katsavelis D; Huizer TF; Zundo G; Hoogeveen-Westerveld M; Oussoren E; van den Hout HJMP; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
    Hum Gene Ther; 2024 Apr; 35(7-8):256-268. PubMed ID: 38085235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome.
    Hong Y; Yu SS; Kim JM; Lee K; Na YS; Whitley CB; Sugimoto Y; Kim S
    J Gene Med; 2003 Jan; 5(1):18-29. PubMed ID: 12516048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow transplantation in a Hunter patient with P266H mutation.
    Coppa GV; Gabrielli O; Cordiali R; Villani GR; Di Natale P
    Int J Mol Med; 1999 Oct; 4(4):433-6. PubMed ID: 10493987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome).
    Bunge S; Steglich C; Beck M; Rosenkranz W; Schwinger E; Hopwood JJ; Gal A
    Hum Mol Genet; 1992 Aug; 1(5):335-9. PubMed ID: 1303211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.